Now Accepting LOIs for the Young Investigator and Pilot Awards
The 2025 Young Investigator Award Letters of Intent (LOI) are due May 30 and Pilot Award Grant LOI is due March 21! Check the Research Grants for updates.
$8,000,000 in research grants
20+ publications resulting from 45+ funded projects and presentations conducted by 36+ investigators
40+ investigators,
over 10 countries represented
Complex Lymphatic Anomaly (CLA) is an umbrella term encompassing four overlapping but distinct rare diseases of the lymphatic system; Gorham Stout Disease (GSD); Generalized Lymphatic Anomaly (GLA); Kaposiform Lymphangiomatosis (KLA); and Central Conducting Lymphatic Anomaly (CCLA). CLAs are characterized by growth of abnormal lymphatic tissue involving both soft tissue and bone leading to chronic and debilitating conditions that can be fatal.
The LMI is a 501(c)3 organization that was established in 2010 to support research that drives our understanding of the pathobiology and genetics of CLAs. The institute also supports and funds clinical and translational research to better define the impact of CLAs on our patients, testing of new therapies and finding biomarkers of disease activity and treatment response. LMI fosters an interactive and collaborative research community inclusive of patients and research and medical professionals, where our research drives improved quality of life and ultimately cures for patients with CLAs.
The 2025 Young Investigator Award Letters of Intent (LOI) are due May 30 and Pilot Award Grant LOI is due March 21! Check the Research Grants for updates.